busilvex 60mg10ml concentrate for solution for infusion ampoules
pierre fabre ltd - busulfan - solution for infusion - 6mg/1ml
navelbine 20mg capsules
pierre fabre ltd - vinorelbine tartrate - oral capsule - 20mg
navelbine 30mg capsules
pierre fabre ltd - vinorelbine tartrate - oral capsule - 30mg
clarelux 500micrograms/g foam
pierre fabre ltd - clobetasol propionate - cutaneous foam - 500microgram/1gram
rosiced 0.75% cream
pierre fabre dermo-cosmetique - metronidazole - cutaneous cream - 7.5mg/1gram
navelbine 80mg capsules
pierre fabre ltd - vinorelbine tartrate - oral capsule - 80mg
javlor 250mg10ml concentrate for solution for infusion vials
pierre fabre ltd - vinflunine ditartrate - solution for infusion - 25mg/1ml
javlor 50mg2ml concentrate for solution for infusion vials
pierre fabre ltd - vinflunine ditartrate - solution for infusion - 25mg/1ml
navelbine oral vinorelbine 80mg (as tartrate) capsule blister pack
pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.
navelbine oral vinorelbine 30mg (as tartrate) capsule blister pack
pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 41.55 mg (equivalent: vinorelbine, qty 30 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide red; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.